EUCTR2018-001059-12-GB进行中（未招募）1 期
An open-label, single arm, multi-centre, phase II study investigating safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of imlifidase (IdeS) in patients with Guillain-Barré Syndrome (GBS), in comparison with matched control patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed Informed Consent obtained before any study-related procedures.
- •2. Willingness and ability to comply with the protocol.
- •3. Male or female aged =18 years at the time of screening.
- •4. GBS diagnosed according to National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria (Asbury et al. 1990)
- •5. Onset of weakness due to GBS is not more than 10 days prior to screening.
- •6. Unable to walk unaided for >10 meters (grade = 3 on GBS DS).
- •7. IVIg treatment being considered.
- •8. Women of child-bearing potential willing or able to use at least one highly effective contraceptive method from the day of treatment until at least 6 months after the dose of imlifidase if not abstinent. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- •9. Men willing to use double-barrier contraception from the day of treatment until at least 2 months after the dose of imlifidase if not abstinent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Previous treatment with imlifidase.
- •2. Previous IVIg treatment within 28 days prior to imlifidase treatment.
- •3. Subjects who are being considered for, or already on, PE.
- •4. Women of childbearing potential who are not willing to use contraception from the screening visit until at least 180 days following imlifidase dosing.
- •5. Breastfeeding or pregnancy
- •6. Clinical evidence of a polyneuropathy of another cause e.g. diabetes mellitus (except mild sensory), alcoholism, vitamin deficiency, or porphyria.
- •7. Known selective IgA deficiency.
- •8. Hypersensitivity to IVIg or to any of the excipients.
- •9. Immunosuppressive treatment (e.g. azathioprine, cyclosporine, mycofenolatemofetil, tacrolimus, sirolimus or > 20 mg prednisolone daily) during the last month.
- •10. Subject known to have a severe concurrent disease, e.g. malignancy, severe cardiovascular disease and severe chronic obstructive pulmonary disease (COPD).
- •11. Any condition that in the opinion of the investigator could increase the subject's risk by participating in the study or confound the outcome of the study.
- •12. Known mental incapacity or language barriers precluding adequate understanding of the Informed Consent information and the study activities.
- •13. Subjects with clinical signs of ongoing infectious diseases that requires treatment.
- •14. Subjects who have received other investigational drugs within 5 halflives prior to imlifidase dosing.
- •A subject will be withdrawn from the study if more than 12 days elapse between the onset of weakness and planned imlifidase administration, thus preventing that the administration of IVIg after imlifidase administration would be later than 14 days after onset of weakness.
研究者
相似试验
进行中（未招募）
1 期
A clinical study investigating the safety and effect of Imlifidase (IdeS) in patients with Guillain-Barré Syndrome (GBS)Guillain-Barré Syndrome (GBS)MedDRA version: 26.0Level: LLTClassification code 10018766Term: Guillain Barre syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-001059-12-NLHansa Biopharma AB30
已完成
2 期
An open-label, single arm, multi-centre, phase II study investigating safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of imlifidase (IdeS) in patients with Guillain-Barré Syndrome (GBS), in comparison with matched control patientsGuillain Barré Syndrome1002766510029305NL-OMON52611Hansa Biopharma AB10
进行中（未招募）
不适用
A study to investigate the efficacy and safety of the PC-A11 treatment in patients with head and neck cancers.Recurrent head and neck squamous cell carcinoma (HNSCC) insuitable for surgery and radiotherapyMedDRA version: 17.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003751-19-ESPCI Biotech AS92
进行中（未招募）
不适用
A study to investigate the efficacy and safety of the PC-A11 treatment in patients with head and neck cancers.Recurrent head and neck squamous cell carcinoma (HNSCC) insuitable for surgery and radiotherapyMedDRA version: 18.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003751-19-LTPCI Biotech AS99
进行中（未招募）
1 期
A study to investigate the efficacy and safety of the PC-A11 treatment in patients with head and neck cancers.Recurrent head and neck squamous cell carcinoma (HNSCC) insuitable for surgery and radiotherapyMedDRA version: 18.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003751-19-GBPCI Biotech AS99